ReShape Other Operating Expenses from 2010 to 2024

RSLS Stock  USD 0.24  0.01  4.00%   
ReShape Lifesciences Other Operating Expenses yearly trend continues to be comparatively stable with very little volatility. Other Operating Expenses is likely to outpace its year average in 2024. Other Operating Expenses is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. View All Fundamentals
 
Other Operating Expenses  
First Reported
2005-03-31
Previous Quarter
5.3 M
Current Value
3.9 M
Quarterly Volatility
2.6 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ReShape Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ReShape Lifesciences' main balance sheet or income statement drivers, such as Interest Expense of 24.7 K, Other Operating Expenses of 26.5 M or Total Operating Expenses of 24.6 M, as well as many indicators such as Price To Sales Ratio of 0.16, Dividend Yield of 0.0 or PTB Ratio of 0.21. ReShape financial statements analysis is a perfect complement when working with ReShape Lifesciences Valuation or Volatility modules.
  
Check out the analysis of ReShape Lifesciences Correlation against competitors.
For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.

Latest ReShape Lifesciences' Other Operating Expenses Growth Pattern

Below is the plot of the Other Operating Expenses of ReShape Lifesciences over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ReShape Lifesciences. It is also known as ReShape Lifesciences overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. ReShape Lifesciences' Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ReShape Lifesciences' overall financial position and show how it may be relating to other accounts over time.
Other Operating Expenses10 Years Trend
Slightly volatile
   Other Operating Expenses   
       Timeline  

ReShape Other Operating Expenses Regression Statistics

Arithmetic Mean26,273,416
Geometric Mean23,035,301
Coefficient Of Variation33.31
Mean Deviation5,374,903
Median25,256,585
Standard Deviation8,752,132
Sample Variance76.6T
Range39.4M
R-Value0.56
Mean Square Error56.8T
R-Squared0.31
Significance0.03
Slope1,091,700
Total Sum of Squares1072.4T

ReShape Other Operating Expenses History

202426.5 M
202323.3 M
202238.3 M
202141.3 M
202023.8 M
201931 M
201825.1 M

About ReShape Lifesciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include ReShape Lifesciences income statement, its balance sheet, and the statement of cash flows. ReShape Lifesciences investors use historical funamental indicators, such as ReShape Lifesciences's Other Operating Expenses, to determine how well the company is positioned to perform in the future. Although ReShape Lifesciences investors may use each financial statement separately, they are all related. The changes in ReShape Lifesciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ReShape Lifesciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ReShape Lifesciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ReShape Lifesciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Operating Expenses23.3 M26.5 M

Pair Trading with ReShape Lifesciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ReShape Lifesciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ReShape Lifesciences will appreciate offsetting losses from the drop in the long position's value.

Moving against ReShape Stock

  0.55EVH Evolent HealthPairCorr
  0.5OMI Owens MinorPairCorr
  0.48VREX Varex Imaging Corp Fiscal Year End 12th of November 2024 PairCorr
  0.47DH Definitive HealthcarePairCorr
  0.42VEEV Veeva Systems ClassPairCorr
The ability to find closely correlated positions to ReShape Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ReShape Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ReShape Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ReShape Lifesciences to buy it.
The correlation of ReShape Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ReShape Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ReShape Lifesciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ReShape Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for ReShape Stock Analysis

When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.